In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Chromadex (CDXC – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.52.
Selvaraju covers the Healthcare sector, focusing on stocks such as RAPT Therapeutics, MoonLake Immunotherapeutics, and Inovio Pharmaceuticals. According to TipRanks, Selvaraju has an average return of -16.9% and a 29.20% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chromadex with a $4.53 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.37 and a one-year low of $1.15. Currently, Chromadex has an average volume of 122.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
Read More on CDXC:
